Skip to main content
. 2021 Nov 11;8:756922. doi: 10.3389/fmed.2021.756922

Figure 2.

Figure 2

(A) Forest plots for an association between the non-severe and severe liver transplantation (LT) recipients with COVID-19 for the overall immunosuppressants (ISs). (B) Forest plots for an association between the non-severe and severe LT recipients with COVID-19 with a subgroup analysis for the calcineurin inhibitors (CNIs), steroids, antimetabolites, and mammalian target of rapamycin inhibitors (mTORis) therapy.